CK Life Sciences Establishes Sequencio Therapeutics to Advance Therapeutic Cancer Vaccine Portfolio
Key Insights
CK Life Sciences (search) has established Sequencio Therapeutics (search) as a wholly-owned subsidiary dedicated to advancing therapeutic cancer vaccines, marking the third pillar of a strategic reorganization following transactions with TransCode and Dogwood Therapeutics (search).
Sequencio's preclinical portfolio includes investigational cancer vaccines targeting TROP2 (search), which demonstrated 100% tumor growth inhibition in preclinical breast and colorectal cancer mouse studies, along with candidates targeting PRAME (search), PD-L1 (search), B7-H3 (search), and Claudin 6 (search).
The company will present five research abstracts at the AACR Annual Meeting 2026, showcasing advancements in next-generation cancer vaccine technologies based on their proprietary TrueHLA™ Epitope-to-Efficacy™ translational design framework.
CK Life Sciences (search) Int'l., (Holdings) Inc. has announced the establishment of Sequencio Therapeutics (search), a wholly-owned subsidiary dedicated to advancing the company's therapeutic cancer vaccine portfolio. This strategic move represents the third pillar of a comprehensive reorganization aimed at accelerating R&D and enhancing operational execution in the pharmaceutical sector.
Strategic Reorganization Continues
The formation of Sequencio follows previous transactions involving Nasdaq-listed TransCode Therapeutics and Dogwood Therapeutics (search), completed in 2025 and 2024 respectively. These developments are designed to broaden capital access for pharmaceuticals and diagnostics R&D, positioning CK Life Sciences (search) at the forefront of therapeutic cancer vaccine development.
In 2025, CK Life Sciences (search) sold its late-stage melanoma vaccine seviprotimut-L to TransCode in exchange for an equity stake. The integration aims to explore synergies between vaccine-driven immunity and RNA-based mechanisms to address treatment resistance and achieve more durable patient responses.
Therapeutic Cancer Vaccine Platform
Sequencio Therapeutics (search) consolidates CK Life Sciences (search)' therapeutic cancer vaccine research under a dedicated organization, reflecting the company's strategic focus on this emerging class of cancer immunotherapy. The subsidiary develops therapeutic cancer vaccines designed to train patients' immune systems to achieve durable, long-term remission with favorable safety profiles.
The platform supports a long-term vision of shifting cancer treatment paradigms from transient tumor reduction toward sustained, immune-controlled remission. Vaccine discovery and design are conducted in-house, with development advanced through internal capabilities and external collaborations.
Preclinical Portfolio Shows Promise
Sequencio's preclinical portfolio includes investigational cancer vaccines targeting Trophoblast Cell Surface Antigen 2 (TROP2 (search)), which demonstrated robust T-cell immune responses and achieved 100% tumor growth inhibition in preclinical breast and colorectal cancer mouse studies. The portfolio also encompasses vaccine candidates targeting PRAME (search) (Preferentially Expressed Antigen in Melanoma), PD-L1 (search) (programmed cell death ligand 1), B7-H3 (search) (B7 homolog 3), and Claudin 6 (search).
"The establishment of Sequencio marks a significant milestone in our ongoing commitment to transforming cancer treatment," said Dr Melvin Toh, Chief Scientific Officer at CK Life Sciences (search). "By consolidating our cancer vaccine research under a dedicated entity, we are establishing a focused platform with the agility and expertise required to drive breakthrough science from the laboratory to the clinic."
Scientific Advancement at AACR 2026
Sequencio will present five research abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22 in San Diego. These presentations mark Sequencio's first major scientific unveiling since its formation and showcase significant advancements in next-generation cancer vaccine technologies.
The presentations highlight Sequencio's proprietary TrueHLA™ Epitope-to-Efficacy™ translational design framework, which enables rational, data-driven vaccine development across circRNA, mRNA, peptide, and protein-based platforms. The data demonstrate rationally designed cancer vaccines with robust immunogenicity and compelling anti-tumor activity across multiple targets and modalities in preclinical models.
Clinical Development Strategy
Building on its preclinical foundation, Sequencio is prioritizing its most promising programs for IND-enabling studies, with the goal of accelerating select vaccine candidates into early-stage clinical development through strategic partnerships and global collaboration.
"Sequencio's cancer vaccine pipeline continues to advance with strong momentum," expressed Dr Melvin Toh. "Our AACR 2026 presentations underscore both the scientific promise of our vaccines and the disciplined execution driving their progress."
Diversified R&D Platform
With Sequencio, TransCode, and Dogwood, CK Life Sciences (search) now offers an R&D platform with a diversified pipeline of early and late-stage projects targeting substantial unmet medical needs. Dogwood Therapeutics (search) is advancing Halneuron® for chemotherapy-induced neuropathic pain, which has demonstrated positive interim Phase 2b results, and has secured a global license to develop an intravenous formulation of SP16 for cancer-related pain.
"By leveraging strategic partnerships, access to public markets, and focused internal development, we are combining the agility of dedicated teams with the resources needed to advance groundbreaking sciences," added Mr Alan Yu, Deputy Chairman of CK Life Sciences (search). "As our R&D projects mature, we may need to consider expanding our R&D facilities in an innovative and hi-tech zone like that of Hong Kong's Northern Metropolis."